Professor Jiro Yasuda and his team from the University of the Japanese city of Nagasaki was able to invent a new method of determining the Ebola virus, which is currently raging in the countries of West and Central Africa. The new method, according to its developers, many times cheaper and faster determines virus than all presently known methods.
According to The Health Site, is currently used to determine fever method so-called polymerase chain reaction. This is a method in molecular biology, which allows for increasing the concentration of certain small DNA fragments in biological material.
The existing process consists of three cycles of repeated reactions for which samples were alternately heated and cooled. This process takes about two hours. Yasuda and his colleagues have proposed an improved method for the determination of the virus in the human body.
The scientist claims that his team was able to create a piece of RNA that amplifies genes of Ebola. Under the RNA ribonucleic acid is understood. It is one of three major macromolecules contained in the cells of all living organisms.
The resulting RNA fragment Japanese scientist proposes to use as a primer, that is, as a short piece of nucleic acid that serves to initiate the synthesis of new DNA strand. According to the idea of the Japanese scientist, you have to take a DNA sample of the patient and reduce the primer, and then heated to 60-65 degrees. If the sample turns cloudy 30 minutes, that is, begin to rise gene of Ebola, the patient is an urgent need to provide assistance.
“The new method is simpler and can be used in countries where the equipment for testing is not available,” – said the professor. He also added that the new method “requires a little heat from the battery and the system costs a few hundred dollars” that affected countries are able to spend on its purchase.
According to statistics, from 25% to 90% of those infected with Ebola die. In late August, the Japanese authorities have announced that they have a drug that may become the vaccine of fever. In fact, the proposal means the Japanese government turned against influenza called Favipiravir.
Earlier with fever and tried to fight with the help of an experimental vaccine ZMapp, which is in itself a “cocktail” of drugs that have been developed by companies from the United States and LeafBio Defyrus Inc. from Canada. Presumably via a ZMapp from Ebola cured two American doctors – Kent Brantley and Nancy Raytbol. Another physician – a citizen of Liberia Abraham Borbor – also took ZMapp, but to cope with the fever he failed.
In the United States, scientists in the near future are going to begin to test a new vaccine against Ebola has on a person. This vaccine, as reported by CNN, was developed by the pharmaceutical companies GlaxoSmithKline and NIAID. Initially, the vaccine will be tested in three healthy volunteers, to see whether it does not cause side effects.
In mid-August, it was reported that an experimental drug to combat Ebola created in Nigeria, calling it Nanosilver. On any results of treatment with it has not yet been reported. The World Health Organization (WHO) has sanctioned the fight against Ebola vaccines have not undergone clinical trials, August 12 this year.
On receipt of a vaccine against Ebola and Russian officials said. “Out of Guinea returned the advance party – the Institute of Ivanovo Health Ministry and a member of one of the centers Rospotrebnadzora. We know the agent and its characteristics, now we have an experimental vaccine that has passed pre-clinical trials with good results,” – said the head of the Ministry of Health on August 26 Veronika Skvortsova.
According to WHO, the world’s been more than three thousand cases of infection with Ebola virus, of which 1552 – fatal. WHO fears that the number of people infected may soon exceed the bar in 20 thousand. Cases have previously been recorded in Liberia, Sierra Leone, Guinea, Nigeria, Senegal and the Democratic Republic of the Congo. According to Reuters, the number of victims in the Congo fever has reached 31.Follow us in social media: